Strides Shasun scrip's health deteriorates despite strong Q1FY17

Strides Shasun has declared its Q1FY17 results on Wednesday. The company’s revenue has increased by 43 per cent to Rs 870 crore in Q1FY17 on a yearly basis. Its EBITDA too has risen by 63 per cent to Rs 144 crore in Q1FY17 as compared to same period in previous financial year. Strides Shasun’s EBITDA margin has expanded by 203 basis points to 16.52 per cent in Q1FY17 on a yearly basis. The company’s PAT stands at Rs 41.7 crore in Q1FY17.

Business segment wise, Strides Shasun has earned 42.6 per cent from regulated markets, 16.63 per cent from emerging markets, 15.84 per cent from institutional business, 24.92 per cent from Pharmaceutical Services and Active Ingredients (PSAI) during Q1FY17.

Strides Shasun has spent about Rs 22.8 crore on R&D against Rs 13 crore in Q1FY16. The company has 53 cumulative ANDA filings with USFDA including one product filed during Q1FY17. Its 27 ANDA filings are pending for approval from USFDA. Strides Shasun has 18 cumulative  U.S. President's Emergency Plan for AIDS Relief (PEPFAR) filings with 17 tentative approvals. 

Strides Shasun has completed its acquisition of strategic stake in Generic Partners Holdings, Australia. The share price of company has declined by 3.52 per cent on bourses; and is trading at Rs 1073.55 on an intraday basis.

Strides Shasun develops and manufactures intellectual property (IP)-led pharmaceutical products. It operates through Pharmaceutical and Biotech segments.